New Huntington's Disease Drug Could Reduce Toxic Protein

A new trial shows a single dose of the drug brezosiran significantly lowered harmful protein levels in study participants.

Updated on Oct. 24, 2026 in Alzheimer’s

A clear glass pipette tip on a clean white laboratory surface, representing precision in pharmaceutical research. — Researchers reported that a single dose of the investigational drug brezosiran successfully reduced toxic huntingtin protein levels in a clinical trial for Huntington's disease patients. AI Illustration. Upload story photo >

Live Poll

Should medical trials prioritize reducing biological markers over showing direct improvements in patient disease symptoms?

A high-dose, single-dose trial of the drug brezosiran successfully reduced mutant huntingtin proteins in the spinal fluid of patients with Huntington's disease. While these initial findings are promising, the study has not yet demonstrated that the drug effectively slows disease progression.

Why it matters

Reducing levels of the toxic mutant huntingtin protein is a primary target in managing the underlying cause of Huntington's disease. This trial marks a critical safety and tolerability milestone for a therapy aimed at disease modification in adult patients.

In a randomized, double-blind, placebo-controlled trial of 48 adults, the highest-dose group achieved a mean mutant huntingtin reduction of 60% to 64% three months after a single dose. These findings remain preliminary, and clinical efficacy on disease progression has not been established.

The players

Alnylam Pharmaceuticals

A biopharmaceutical company specializing in RNA interference therapeutics for genetic diseases.

The details

The investigational drug brezosiran works by targeting the production of the toxic huntingtin protein at the genetic level through a single intrathecal injection. By reducing the accumulation of these proteins in the central nervous system, researchers aim to address the biological root of the condition. Researchers monitored inflammatory markers, neurofilament light chain, and brain volume, finding no dose-related increases in these safety metrics during the 12-month follow-up.

Sept. 10, 2026: Assessment date for serious adverse events.
Oct. 23, 2026: Alnylam Pharmaceuticals announced trial results.
2027: Planned launch of a placebo-controlled efficacy study.

Health Landscape

This development aligns with the ongoing shift toward gene-silencing therapies in the treatment of Huntington's disease. It marks a meaningful step in exploring how therapeutic interventions can safely modify the underlying protein pathology associated with the condition.

Patients and their families should note that while this drug reduced toxic proteins, it has not yet proven clinical benefit in slowing the disease. These findings are foundational for future studies and should be discussed with a neurologist to understand ongoing trial developments.

The takeaway

This study demonstrates that targeting the mutant huntingtin protein with a single dose is feasible and safe at current dosages. Families should follow upcoming trial announcements regarding clinical efficacy, which remain the critical next step in determining the drug's value.

What happens next

Alnylam Pharmaceuticals is scheduled to initiate a larger, placebo-controlled study in 2027 to evaluate whether brezosiran can effectively slow the clinical progression of Huntington's disease.